ライフサイエンスコーパス: nonmyeloablative conditioning

1 lloengraftment and tolerance induction under nonmyeloablative conditioning.

2 Two had nonmyeloablative conditioning.

3 the donor chimerism in recipients receiving nonmyeloablative conditioning.

4 in 21% receiving myeloablative vs. 12% with nonmyeloablative conditioning.

5 entical living-related donors after modified nonmyeloablative conditioning.

6 sed risk of failure of engraftment following nonmyeloablative conditioning.

7 = .009) and better survival (P = .04) after nonmyeloablative conditioning.

8 improve survival after allogeneic HCT after nonmyeloablative conditioning.

9 itumor responses similar to those seen after nonmyeloablative conditioning.

10 ng cells, was infused into the patient after nonmyeloablative conditioning.

11 e disappearance of gene-modified cells after nonmyeloablative conditioning.

12 163 patients undergoing allogeneic HCT with nonmyeloablative conditioning.

13 ns (RLIs) to mixed chimeras established with nonmyeloablative conditioning.

14 iagnosed with advanced CLL were treated with nonmyeloablative conditioning (2 Gy total-body irradiati

15 wk of age using MHC-matched donor cells and nonmyeloablative conditioning (550 cGy irradiation).

16 Many patients received nonmyeloablative conditioning; a significant proportion

17 We demonstrate that nonmyeloablative conditioning achieves mixed hematopoiet

18 nt long-term benefit when patients are given nonmyeloablative conditioning and ADA enzyme-replacement

19 administration of HAART was feasible during nonmyeloablative conditioning and after HCT.

20 nolate mofetil, was first demonstrated after nonmyeloablative conditioning and allografting using hum

21 In the present studies, we demonstrate that nonmyeloablative conditioning and BM cell infusion modul

22 ts in MHC-mismatched nonhuman primates after nonmyeloablative conditioning and donor bone marrow tran

23 sm was transient, which was most common with nonmyeloablative conditioning and fully rather than hapl

24 patients with advanced CLL when treated with nonmyeloablative conditioning and hematopoietic cell tra

25 Four of five dogs with CLAD that received nonmyeloablative conditioning and infusion of autologous

26 equency and severity of hepatic injury after nonmyeloablative conditioning and its relationship to ou

27 This promotes engraftment even after nonmyeloablative conditioning and limits graft-versus-ho

28 Eight monkeys underwent nonmyeloablative conditioning and major histocompatibili

29 Baboon BMT to treat AIDS was attempted using nonmyeloablative conditioning and resulted in transient

30 ells can be induced after fludarabine-based, nonmyeloablative conditioning and that it serves as a pl

31 in a subgroup of patients who had undergone nonmyeloablative conditioning and transplantation.

32 established lupus-like disease that received nonmyeloablative conditioning and transplants of (MHC) h

33 ression analysis: use of 2 UCB units, use of nonmyeloablative conditioning, and absence of antithymoc

34 In the present studies, we used a nonmyeloablative conditioning approach to establish chim

35 hese findings support the use of UCB after a nonmyeloablative conditioning as a strategy for extendin

36 s had enhanced short-term engraftment, after nonmyeloablative conditioning, as compared to controls.

37 Thus, tailoring the intensity of nonmyeloablative conditioning based on prior chemotherap

38 Tolerance with a nonmyeloablative conditioning can allow successful pancr

39 ties of overall survival of 41% and 29% with nonmyeloablative conditioning compared with 45% and 24%

40 all survival at 2 years of 70% and 57% after nonmyeloablative conditioning compared with 78% and 50%

41 matopoietic cell transplantation (HCT) after nonmyeloablative conditioning consisting of 2 Gy total b

42 In a canine model of allogeneic HCT after nonmyeloablative conditioning, DST to skin grafts was ev

43 Mixed chimeras prepared with low-intensity nonmyeloablative conditioning exhibit systemic tolerance

44 Seventy-one patients received nonmyeloablative conditioning, fludarabine (30 mg/m(2)/d

45 Nonmyeloablative conditioning followed by a T-cell-deple

46 shed in mismatched kidney recipients through nonmyeloablative conditioning followed by infusion of a

47 this area will help to establish the role of nonmyeloablative conditioning for allografting.

48 e mechanism for total body irradiation-based nonmyeloablative conditioning for BM transplantation, an

49 matopoietic cell transplantation (HCT) after nonmyeloablative conditioning for hematologic malignanci

50 gs have uncomplicated parturitions following nonmyeloablative conditioning for SCT.

51 Nonmyeloablative conditioning (group 1) in the absence o

52 crease of IgM and IgG) in baboons undergoing nonmyeloablative conditioning (group 2).

53 Nonmyeloablative conditioning has significantly reduced

54 plantation of purified allogeneic HSCs after nonmyeloablative conditioning has the potential to rever

55 matopoietic cell transplantation (HCT) after nonmyeloablative conditioning in 64 patients who had adv

56 and consider reduced intensity conditioning/nonmyeloablative conditioning in patients who have achie

57 matopoietic cell transplantation (HCT) after nonmyeloablative conditioning in patients with hematolog

58 outcomes were seen with allogeneic HCT after nonmyeloablative conditioning in selected patients who h

59 blative conditioning but is persistent after nonmyeloablative conditioning, in which recipient hemato

60 Mixed chimerism established by nonmyeloablative conditioning induces long-term acceptan

61 Allogeneic HCT after nonmyeloablative conditioning is a promising salvage str

62 Although the major role for nonmyeloablative conditioning is to control alloreactive

63 Invasive mold infections occurred late after nonmyeloablative conditioning (median, day 107), with pr

64 oablative regimens suggested that the use of nonmyeloablative conditioning might be associated with l

65 ematopoietic stem cell transplantation after nonmyeloablative conditioning might become the procedure

66 s-leukemia effects, and allogeneic HCT after nonmyeloablative conditioning might prolong median survi

67 The role of allogeneic transplant with nonmyeloablative conditioning needs to be explored furth

68 = 165), reduced intensity (RIC; n = 143), or nonmyeloablative conditioning (NMAC; n = 88) regimens.

69 ortality among 60 consecutive patients given nonmyeloablative conditioning (nonablative patients) to

70 ed in laboratory animals and in humans after nonmyeloablative conditioning of the host and infusion o

71 ity was estimated at 22% (36 patients) after nonmyeloablative conditioning, of which 39% (14 patients

72 s has prompted the development of less toxic nonmyeloablative conditioning protocols, the goal of whi

73 CI, 1.39-13.81]), and in the late phase were nonmyeloablative conditioning regimen (HR, 35.08 [95% CI

74 In another study, baboons (n=9) received a nonmyeloablative conditioning regimen (NMCR) aimed at in

75 rsus-host disease (GVHD) in mice receiving a nonmyeloablative conditioning regimen allowing establish

76 ve T cells in mixed chimeras prepared with a nonmyeloablative conditioning regimen and allogeneic bon

77 arrow transplantation using a short-duration nonmyeloablative conditioning regimen and posttransplant

78 We have previously described a nonmyeloablative conditioning regimen based on recipient

79 We used a nonmyeloablative conditioning regimen consisting of cycl

80 We have used a nonmyeloablative conditioning regimen consisting of tota

81 issue of Blood, Muller et al showed, using a nonmyeloablative conditioning regimen consisting of tota

82 Here, we ask whether a nonmyeloablative conditioning regimen establishing mixed

83 afts undergoing this complete short-duration nonmyeloablative conditioning regimen had durable lung a

84 A nonmyeloablative conditioning regimen has recently been

85 ound for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction wit

86 Mixed hematopoietic chimerism induced with a nonmyeloablative conditioning regimen leads to donor-spe

87 Using a GVHD protective nonmyeloablative conditioning regimen of total lymphoid

88 n anti-alphaGal antibody production; (iii) a nonmyeloablative conditioning regimen reduces the rate o

89 ppa light-chain multiple myelomas received a nonmyeloablative conditioning regimen that consisted of

90 We took advantage of a nonmyeloablative conditioning regimen that permits allog

91 oxp3+ regulatory T cells (Tregs) surviving a nonmyeloablative conditioning regimen that undergo robus

92 design of clinical trials using (213)Bi as a nonmyeloablative conditioning regimen with minimal toxic

93 Group 1 received a nonmyeloablative conditioning regimen without porcine BM

94 elf-derived differentiation antigens after a nonmyeloablative conditioning regimen.

95 combination by using a relatively nontoxic, nonmyeloablative conditioning regimen.

96 irradiation (TBI) were compared as part of a nonmyeloablative conditioning regimen.

97 o investigate the effect of a pharmacologic, nonmyeloablative, conditioning regimen on the developmen

98 Recent clinical reports suggest that nonmyeloablative conditioning regimens afford better out

99 Nonmyeloablative conditioning regimens are increasingly

100 This has prompted the recent development of nonmyeloablative conditioning regimens for allogeneic he

101 ype may therefore have an adjunctive role in nonmyeloablative conditioning regimens for allogeneic st

102 ens, and they provide support for the use of nonmyeloablative conditioning regimens in preclinical pr

103 re, our studies suggest the possibility that nonmyeloablative conditioning regimens might be effectiv

104 Transplantation with nonmyeloablative conditioning regimens relying on the gr

105 Less toxic nonmyeloablative conditioning regimens that have the pot

106 inition of high-dose, reduced-intensity, and nonmyeloablative conditioning regimens, the most commonl

107 treatment-related mortality associated with nonmyeloablative conditioning regimens, the question of

108 oviral-mediated gene therapy in CLAD using 2 nonmyeloablative conditioning regimens--200 cGy total bo

109 ols in cases of limited graft cell number or nonmyeloablative conditioning regimens.

110 In summary, following nonmyeloablative conditioning, simultaneous administrati

111 PS was significantly lower at 120 days after nonmyeloablative conditioning than conventional conditio

112 unrelated donors who successfully underwent nonmyeloablative conditioning therapy followed by infusi

113 Nonmyeloablative conditioning using total lymphoid irrad

114 In murine mixed chimeras prepared with nonmyeloablative conditioning, we previously showed that

115 ing the first year after allogeneic HCT with nonmyeloablative conditioning were 19%, 15%, 14%, and 5%

116 c stem cell (HSC) engraftment following this nonmyeloablative conditioning were evaluated.

117 Patients given nonmyeloablative conditioning were older than those give

118 Patients receiving nonmyeloablative conditioning were older, more frequentl

119 t factor predicting lessened RRT and NRM was nonmyeloablative conditioning, whereas high pretransplan

120 The results suggest that nonmyeloablative conditioning with (213)Bi-labeled anti-

121 Nonmyeloablative conditioning with 200 cGy TBI and anti-

122 nt study, we tested BDDpfVIII activity after nonmyeloablative conditioning with busulfan, cyclophosph

123 opoietic chimerism can be achieved following nonmyeloablative conditioning with cyclophosphamide, T c

124 ed and refractory mantle cell lymphoma after nonmyeloablative conditioning with fludarabine and 2 Gy

125 -incompatible cells can engraft stably after nonmyeloablative conditioning with immunosuppressive che

126 Group 2 received nonmyeloablative conditioning with pig BM transplantatio

127 Nonmyeloablative conditioning with posttransplantation h

128 hematopoietic stem cell transplantation, and nonmyeloablative conditioning with total lymphoid irradi